Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
BioPharma Dive

Pfizer dips on new data for obesity drug acquired in $10B deal

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...
Fierce Biotech

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders

Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% ...

Pfizer CEO discusses the company's GLP-1 weigh-loss drug pipeline

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

Pfizer’s Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Pfizer made one thing clear this week: It's officially back in the obesity race.

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...